NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

C Reactive Protein (CRP)

; .

Author Information

Last Update: November 13, 2018.


C-reactive protein (CRP) was discovered by Tillett and Francis in 1930. The name CRP arose because it was first identified as a substance in the serum of patients with acute inflammation that reacted with the "c" carbohydrate antibody of the capsule of pneumococcus.

CRP is a pentameric protein synthesized by the liver, whose level rise in response to inflammation. 

There are numerous causes of an elevated C-reactive protein.  These include acute and chronic conditions, and these can be infectious or non-infectious in etiology. However, markedly elevated levels of CRP are most often associated with an infectious cause (an example of pathogen-associated molecular pattern recognition).  Trauma can also cause elevations in CRP (alarmin response). More modest elevations tend to be associated with a broader spectrum of etiologies, ranging from sleep disturbances to periodontal disease.  High-sensitivity CRP only denotes the assay process used, allowing for detection of lower levels of CRP, and not a different, or more specific, differential diagnosis.

CRP is an acute-phase reactant protein that is primarily induced by the IL-6 action on the gene responsible for transcription of CRP during the acute phase of an inflammatory/infectious process. There is some question of whether dysregulation of the role of CRP in clearance of apoptotic cells and cellular debris plays a role in the pathogenesis of systemic lupus erythematosus (SLE), but this has not been definitively demonstrated. It has been demonstrated to have some protective properties in rabbit studies on lung tissue in alveolitis by reducing neutrophil-mediated damage to the alveoli and protein leakage into the lung.

CRP has both proinflammatory and anti-inflammatory properties. It plays a role in recognition of foreign pathogens and damaged cells by binding to the phosphocholine arm when it is present. It can activate the complement system and also activates phagocytic cells via Fc receptors to expedite removal of cellular debris and damaged or apoptotic cells and foreign pathogens. This can become pathologic, however, when it is activated by antibodies displaying the phosphocholine arm in auto-immune processes, such as idiopathic thrombocytopenic purpura (ITP). It can also worsen tissue damage in certain cases due to activation of the complement system and thus inflammatory cytokines.

Specimen Collection

A blood specimen is taken from a peripheral venous draw. The patient's medications should be reviewed, as these can affect the outcome of the test. Fasting is not required before the blood draw. There are no special procedures required. The specimen takes only a few minutes to obtain.  Complications include oozing at the draw site, bruising or mild tenderness at the site, or very rarely, infection at the venipuncture site.

A phlebotomist performs the procedure in most cases. The phlebotomist secures a snug, rubber band around the upper arm, and the patient pumps his or her fist several times. The phlebotomist palpates the vein to confirm the location and cleanses the area with an alcohol prep pad. Once the area air dries, the practitioner introduces a needle into the vein and draws a vial of blood. He or she removes the band from the patient's arm, and then removes the needle and applies pressure to the venipuncture site until hemostasis occurs, usually within one minute. A bandage is applied over the site, and the test is complete.

Other bodily fluids, such as synovial fluid, can be tested for in this manner, but frequently are not.


This test is performed when the physician suspects acute or chronic inflammation (e.g, SLE or rheumatoid arthritis (RA)) or infection. There are some that also use this as a cardiac screening tool (hs-CRP); however, studies are underway to determine the validity of this application for the test, as it is elevated in so many other conditions (e.g, diabetes, insomnia, stress, inflammation). There is some correlation between cardiovascular risk and elevated hs-CRP, but the application of this is still controversial among various groups of physicians,  and it is currently undergoing more study.

Normal and Critical Findings

Lab values vary, and there is no standard at present.  However, in general, the results is reported in either mg/dL or mg/L. Hs-CRP is usually reported in mg/L. Levels in the 0.3 mg/dL to -1 mg/dL are considered mild and are usually seen with diabetes, hypertension (HTN), periodontitis, sedentary lifestyle, cigarette smoking, and many other non-inflammatory processes. In general, significant inflammation or infection is considered present at levels greater than 1 mg/dL. Levels greater than 10 mg/dL are usually related to acute bacterial infection. Viral infections will also elevate CRP, but not to the same degree as other etiologies.  When compared to ESR in an infectious state, CRP will rise and fall more rapidly. In autoimmune states, it may not have the same level of elevation as ESR.

There is also an early study demonstrating that there is a correlation between stroke recurrence within one year and elevated hs-CRP coupled with a National Insitute of Health Stroke Scale (NIHSS) greater than 6, after initial acute ischemic stroke. When coupled with elevated alpha-defensin levels, CRP testing done on synovial fluid has been shown in one small study to be highly sensitive and specific for peri-prosthetic infection when CRP was greater than 3 mg/L in the fluid.

When used for cardiac risk stratification, hs-CRP levels less than 1 mg/dL are considered low risk. Levels between 1 mg/dL and 3 mg/dL are considered moderate risk and a level greater than 3 mg/dL is considered high risk for development of cardiovascular disease.

Interfering Factors

Certain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) will falsely decrease CRP levels. Statins, as well, have been known to reduce CRP levels falsely. The decreased CRP levels occur with both NSAIDs and statins because these drugs reduce inflammatory response in the body. Recent injury or illness can falsely elevate levels, particularly when using this test for cardiac risk stratification. Magnesium supplementation also can decrease CRP levels.


Given the highly variable causality of elevated CRP, marginal elevations in the CRP can be difficult to interpret and should not be used as an isolated test result interpreted as appropriate for the clinical picture. It is useful in suggesting infection versus inflammation if the levels are extremely high, but levels from 1 mg/dL to 10 mg/dL can be difficult to interpret accurately. Chronic conditions, such as arthritis or lupus, can make these levels elevated chronically, making it harder to determine if there is any significance to an elevated hs-CRP level when using it as a predictive marker for cardiovascular disease.

Clinical Significance

High levels of CRP, greater than 10 mg/dL, are associated with infection about 80% of the time. If the level exceeds 50%, then that number rises to around 94%. Numbers greater than 1 mg/dL are considered to be associated with clinically significant inflammation.


To access free multiple choice questions on this topic, click here.


Shangwei Z, Yingqi W, Jiang X, Zhongyin W, Juan J, Dafang C, Yonghua H, Wei G. Serum High-Sensitive C-Reactive Protein Level and CRP Genetic Polymorphisms Are Associated with Abdominal Aortic Aneurysm. Ann Vasc Surg. 2017 Nov;45:186-192. [PubMed: 28549956]
Simental-Mendia LE, Sahebkar A, Rodriguez-Moran M, Zambrano-Galvan G, Guerrero-Romero F. Effect of Magnesium Supplementation on Plasma C-reactive Protein Concentrations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr. Pharm. Des. 2017;23(31):4678-4686. [PubMed: 28545353]
Zhang YB, Yin Z, Han X, Wang Q, Zhang Z, Geng J. Association of circulating high-sensitivity C-reactive protein with late recurrence after ischemic stroke. Neuroreport. 2017 Jul 05;28(10):598-603. [PubMed: 28542069]
Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007 Jan;81(1):1-5. [PubMed: 17032697]
Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med. 2008 Oct;264(4):295-314. [PubMed: 18823504]
Vanderschueren S, Deeren D, Knockaert DC, Bobbaers H, Bossuyt X, Peetermans W. Extremely elevated C-reactive protein. Eur. J. Intern. Med. 2006 Oct;17(6):430-3. [PubMed: 16962952]
Kushner I. The phenomenon of the acute phase response. Ann. N. Y. Acad. Sci. 1982;389:39-48. [PubMed: 7046585]
Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 2001 Aug;38(2-3):189-97. [PubMed: 11532280]
Ahmed N, Thorley R, Xia D, Samols D, Webster RO. Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am. J. Respir. Crit. Care Med. 1996 Mar;153(3):1141-7. [PubMed: 8630558]
Copyright © 2019, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK441843PMID: 28722873


  • PubReader
  • Print View
  • Cite this Page

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...